NRF2 in Multiple Sclerosis MS is a chronic neurodegenerative and autoimmune disease that affects 2.8 million people worldwide and remains one of the most common causes of neurological disability in the young adult population (Jakimovski et al., 2024)
This could lead to incorrect medication strengths, frequency, or refill quantities, ultimately causing billing issues or improper medication dispensing
However, the KFF report indicates that this new trend might have reached its peak
Higher levels are expected during puberty and pregnancy which makes sense as these are primary periods of growth and development
As research continues and higher doses are explored, GLP-1 analogues have the potential to revolutionize weight loss therapies and improve the overall health and well-being of individuals worldwide
A historical look to the future